Application No.	Applicant(s)	
10/038,565	NONOMURA ET AL.	
Examiner	Art Unit	
Frederick F. Krass	1614	
OR REMAINS) CLOSED in this a or other appropriate communication BHTS. This application is subject	correspondence address pplication. If not included on will be mailed in due course. THIS to withdrawal from issue at the initiative	
niner. der 35 U.S.C. § 119(a)-(d) or (f). been received. been received in Application No uments have been received in this der 35 U.S.C. § 119(e) (to a provision or in an Application Data Sheel plication has been received. der 35 U.S.C. §§ 120 and/or 121 s	s national stage application from the	
in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF		
INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient. 8. CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) hereto or 2) to Paper No (b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner. (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).		
6⊠ Interview Summary (7⊠ Examiner's Amendm	atent Application (PTO-152) (PTO-413), Paper No nent/Comment nt of Reasons for Allowance	
	Examiner Frederick F. Krass ars on the cover sheet with the OR REMAINS) CLOSED in this a cor other appropriate communication and MPEP 1308. 11-20-03. Ininer. Ider 35 U.S.C. § 119(a)-(d) or (f). Ideen received. Ideen received in Application No. puments have been received in this interest of the pulcation has been received. Ider 35 U.S.C. § 119(e) (to a provision or in an Application Data Sheet polication has been received. Ider 35 U.S.C. §§ 120 and/or 121 stopplication has been received. Ider 35 U.S.C. §§ 120 and/or 121 stopplication. THIS THREE-MC this communication to file a reply on the pulcation. THIS THREE-MC the pulcation. THIS THREE-MC the pulcation. THIS THREE-MC the pulcation of the attached EXAMINER is reason(s) why the oath or declar be submitted. In section filed, which has been according to 37 CFR 1.121. If of BIOLOGICAL MATERIAL is of BIOLOGICAL MATERIAL is DEPOSIT OF BIOLOGICAL M	

Application/Control Number: 10/038,565

Art Unit: 1614

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Androlia on 12-22-03.

The following changes have been made:

- 1) Claim 1 has been canceled without prejudice thereto.
- 2) The following new claims have been added:
- --- Claim 12. An oral care agent for the treatment of periodontitis, comprising the following components:
 - (a) an antifungal agent selected from the group consisting of amphotericin B, miconazole and fluconazole;
 - (b) a macrolide antibiotic; and

Page 2

Application/Control Number: 10/038,565

Art Unit: 1614

(c) a component selected from the group consisting of a periodontium rebuilding membrane, a periodontium inducing agent, a dental pulp inducing agent, and a component of a prosthesis;

Page 3

wherein components (a) and (b) together are more effective for treating periodontitis than either component alone. ---

--- Claim 20. An oral care agent for the treatment of periodontitis, comprising the following components:

- (a) an antifungal agent selected from the group consisting of amphotericin B, miconazole and fluconazole;
- (b) azithromycin; and
- (c) a component selected from the group consisting of a periodontium rebuilding membrane, a periodontium inducing agent, a dental pulp inducing agent, and a component of a prosthesis;

wherein components (a) and (b) together are more effective for treating periodontitis than either component alone. ----

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frederick Krass whose telephone number is (703) 308-

Art Unit: 1614

4335. The examiner can normally be reached on Monday, Tuesday and Thursday from 9am to 5pm, and on Fridays from 11am to 7pm. The examiner is off Wednesday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel, can be reached at (703) 308-4725. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0193.

Frederick Krass Primary Examiner

Art Unit 1614